154 - Regulatory Considerations for Starting Materials in Drug Substance Development (S11E4)

You know, when you think about what goes into
the medicines you take, it can sometimes feel
like looking into this really complex world.
Yeah, it really can. How are all those ingredients
chosen? And like, who's checking that everything
is, well, up to snuff? That's actually what we're
diving into today. Exactly. And we're zooming
in on something pretty fundamental in drug development
and manufacturing. Starting materials. Starting
materials, OK. And these aren't just, you know,
random chemicals mixed together. Not at all.
They're very specifically selected substances
and they're rigorously controlled right from
the get -go. Right. So the mission for this deep
dive then is to sort of make sense of how these
starting materials get picked, how they're justified.
We want to try and cut through some of that complexity
and show why. this area that sounds really technical
is actually vital for the quality and safety
of the medications people rely on. Think of it
like the foundation, right? The bedrock of the
pharmaceuticals. That's a great way to put it.
And yeah, to give you this understanding, we've
looked at quite a range of sources, you know,
strict guidelines from regulatory bodies, scientific
articles, things like that. all about the drug
development process. OK, fantastic. So let's
get right down to it then. When we talk about
starting materials in the context of making drugs,
what exactly are we referring to? OK. So in drug
substance development that's making the active
ingredient, the API starting materials are specific
substances. They're chosen because they become
significant structural parts of that final API
molecule. Significant structural parts, like
key building blocks. Precisely. Key building
blocks you strategically start with. It's a very
deliberate choice, not just grabbing the first
chemical off the shelf. Got it. So definitely
not arbitrary. There's a real logic behind picking
these specific initial components. Absolutely.
And deciding what counts as a starting material
isn't just a scientific choice. It carries a
significant regulatory weight. Ah. That designation,
that label, it has ripple effects all through
the drug's life cycle. It affects how it's developed,
how it's manufactured, controlled, and ultimately
how it gets approved. Regulatory implications.
OK, that sounds like there must be some pretty
specific rules dictating this whole process.
Oh, definitely. Regulatory bodies like the FDA
in the US or EMA in Europe, they have quite clear
expectations for how starting materials are chosen.
And maybe even more importantly, how companies
justify those choices. Justify them. Yeah. It's
not enough to just say, we use this. You have
to provide a solid rationale, a strong argument
for why it's appropriate to designate that specific
substance as your starting point. And what kind
of rationale are they looking for? What makes
one choice, you know, better or more justifiable
than another in their eyes? Well, the main thing
is usually the material's role in the synthetic
pathway. Like, how does it chemically transform
through the reaction steps to become the API?
But another huge factor is the quality and purity
of the starting material itself. Quality and
purity. Okay. Regulators need assurance that
the foundation you're building on is solid. that's
clean, well -defined. That makes total sense,
because if you start with something impure, those
impurities could, I guess, potentially carry
through and end up in the final medicine. Exactly
right. I mean, you look at regulations like CFR
Title 21, Part 211 in the US. It talks broadly
about protecting all raw materials from contamination
when they arrive during storage. Uh -huh. But
that principle is especially critical for starting
materials because they're so early in the chain
and contribute directly to the API structure.
So, yeah, that initial quality is a major focus
for regulators. Okay. So it's not just identifying
the material. Pharmaceutical companies really
have to build a case for their selection. What
goes into that justification and what are they
looking at? It's a mix, really, scientific and
technical factors. One key thing is the complexity
of the API molecule you're trying to make. How
complex it is. Yeah, if you're building a really
intricate structure, you might reasonably need
to start with something that's already fairly
complex itself, something that already has some
of those key structural features built in. OK,
that makes sense. What other factors play into
justifying a starting material? Another big one
is the number of chemical steps between your
proposed starting material and the final API.
how many reactions are left. Generally speaking,
if you designate something that's very close
structurally to the final API, meaning only a
few chemical steps remain, that starting material
is going to face much tougher scrutiny. So fewer
steps left means more scrutiny on the starting
point. Why is that? The logic is that any impurities
present in that late stage starting material,
have fewer opportunities, fewer purification
steps to be removed before you get to the final
API. The risk of them carrying through is higher.
I see. So it's kind of an inverse relationship
there. Fewer steps remaining makes the starting
material quality even more critical. Exactly.
So the justification needs to convincingly show
that, OK, even if our starting point is quite
similar to the final drug, we have really robust
controls in place. We understand the potential.
impurities, we can test for them, we can manage
them effectively. This whole process, it sounds
like there are quite a few points where things
could, you know, potentially introduce risk.
How do companies think about that proactively?
How do they manage risk right from this early
stage? Yeah, that's absolutely key, and that's
where risk assessment comes in as a really indispensable
tool. Risk assessment, okay. In this context,
for starting materials, Risk assessment is basically
a systematic way to identify potential problem
sources of variability, contamination risks,
and then evaluate how likely they are and what
impact they could have on the final API quality.
And how does actually doing a risk assessment
help with choosing and justifying the starting
material? Well, by digging deep into the manufacturing
process of the starting material itself, where
do its raw materials come from? How is it synthesized?
What side reactions or byproducts might it contain?
Ah, so looking even further back up the chain.
Exactly. By doing that thorough analysis, manufacturers
can pinpoint where variability or contamination
might creep in before it even reaches their own
process. And that allows them to put the right
controls in place much earlier. Testing specifications,
supplier audits, things like that. So it's really
about this deep understanding of the entire supply
chain and manufacturing process, not just for
the API synthesis, but for the materials feeding
into that synthesis, too. Precisely. And this
approach aligns very closely with the broader
principles of quality by design or QBD. We don't
need to get bogged down on all the details of
QBD, but the core idea is being proactive, building
quality, safety, and effectiveness into the product
right from the beginning based on scientific
understanding and risk management. So applying
that risk -based thinking really early on in
development. Yeah, it's fundamental. It's fascinating
how critical this thinking is right at the stage
of selecting those initial building blocks. You've
mentioned these underlying principles, and it
really sounds like even if we're not rattling
off specific regulation numbers constantly, there's
a consistent philosophy guiding this. You're
absolutely right. I mean, we haven't explicitly
mentioned, say, ICH Q11, which is a key guideline
on developing and manufacturing APIs. OK. But
its principles are woven all through this. ICH
Q11 really emphasizes needing a thorough understanding
of the API's synthetic route. And that understanding
is completely fundamental to making informed
choices about starting materials. And why is
having that deep understanding of the whole synthesis
so critical for picking the right starting points?
Because it allows the manufacturers to identify
what are called critical process parameters,
basically, the steps or conditions in the synthesis
that have the biggest impact on the final quality.
of the API. The most sensitive steps. Exactly.
By knowing those critical points throughout the
entire route, they can then figure out the most
appropriate stage to introduce a defined starting
material. And crucially, what quality attributes
that material must have to ensure you end up
with a consistent high quality API. every single
time right it's about building that quality in
from the start not just trying to test for it
or fix problems at the very end that's the essence
of it yeah yeah the ultimate goal is always a
consistent high quality api and that journey
truly begins with meticulously selecting and
controlling those initial starting materials
it makes sense and You know, the choice of starting
material has a very, very direct impact on the
kinds of impurities and the levels of those impurities
that might show up in the final drug substance.
Oh, so. Well, think about it. If you start with
a material that already contains impurities that
are structurally very similar to your target
API, those can be incredibly difficult to separate
out in later purification steps. It's kind of
like trying to separate, I don't know, grains
of sand that look almost identical versus pulling
out a distinct pebble. much harder. That's a
great analogy. Yeah, I can see that. So having
really good analytical methods, ways to detect
and measure these potential impurities, that
becomes absolutely essential then. Absolutely
essential. Companies need sophisticated analytical
tools and validated methods to find and quantify
any significant impurities that might be coming
from the starting materials or formed from them.
Right. And as we sort of touched on earlier with
regulations like CFR 211, the guidelines are
very clear. Manufacturers must have adequate
controls over the quality of their starting materials,
specifically to minimize the risk of any harmful
impurities carrying over into the final drug
product that reaches the patient. It's a multi
-layered safety net. So this whole complex dance
of selecting, justifying, controlling starting
materials. It isn't just like a regulatory checkbox
exercise companies have to tick off. It actually
has real tangible effects on, well, the efficiency
and maybe even the cost of developing and manufacturing
new medicines. Oh, absolutely. No question. A
really well -thought -out, well -justified starting
material strategy can genuinely streamline the
regulatory review process. How? Well, if a company
has clearly done its homework, presents a robust
scientific rationale, shows strong controls,
it just gives regulators more confidence, it
can lead to fewer questions, smoother reviews,
potentially quicker approvals. Okay. Conversely,
if the strategy is weak or poorly justified,
you can expect delays, lots of back and forth
with the agency asking for more data, more justification.
And what about on the actual manufacturing floor?
Does it impact production? Big time. On the manufacturing
side, using starting materials that are well
-characterized and consistently meet their quality
specifications is crucial for a reliable supply
chain. If you have high confidence in the quality
of your initial building blocks, you're much
less likely to run into unexpected problems during
large -scale production, things like batch failures,
yield issues, out -of -spec results. Some sources,
like articles in OPR &D, often point to inconsistencies
in starting material quality as a root cause
when scal - up goes wrong. Right. So it really
does all circle back to this seemingly early
fundamental step of choosing and controlling
the right starting materials. It's not a minor
detail at all. It's really a cornerstone for
ensuring the medicines we rely on are safe, effective,
and consistently available. Precisely. That's
the takeaway. The detailed regulatory scrutiny,
the emphasis on risk assessment throughout this
process, it's all designed to provide that critical
assurance right from those very first chemical
building blocks. It really makes you appreciate
all the sort of unseen work and rigor that goes
into getting a medicine from a lab bench to your
local pharmacy shelf. Thinking about how even
those initial ingredients are so carefully selected
and controlled just highlights the immense complexity
involved. It truly does. And, you know, for listeners
who find this intriguing and want to know more,
the websites of regulatory agencies, FDA, EMA,
others actually have a lot of publicly available
information, guidance documents, reports. explaining
their expectations for pharmaceutical quality,
including starting materials, it could be its
own deep dive. Definitely something worth exploring
if you want to sort of pull back the curtain
even further on how medicines are made. Well,
thank you for shedding so much light on this
absolutely crucial foundational aspect of drug
development today. My pleasure. It's a critical
area.